78,51 $
4,33 % gestern
Nasdaq, 28. Oktober, 21:05 Uhr
ISIN
US74366E1029
Symbol
PTGX
Berichte

Protagonist Therapeutics, Inc. Aktie News

Positiv
Seeking Alpha
17 Tage alt
Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its oral immunology drug icotrokinra and blockbuster potential of rusfertide for polycythemia vera, both with strong partnership structures. A JNJ acquisition could save milestone payments, secure future...
Positiv
The Motley Fool
18 Tage alt
Clinical-stage biotech Protagonist Therapeutics (PTGX 29.76%) was all the rage on the stock market Friday. The company's share price closed a dizzying 29.8% higher on the day, thanks to intense takeover speculation.
Positiv
Reuters
19 Tage alt
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.
Positiv
WSJ
19 Tage alt
The two companies are already codeveloping a treatment for ulcerative colitis.
Neutral
Seeking Alpha
etwa 2 Monate alt
Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 11:30 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Douglas Tsao - H.C.
Neutral
Seeking Alpha
etwa 2 Monate alt
Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director Welcome to the second day of the Citi Biopharma Back to School Summit. I'm ...
Neutral
Accesswire
2 Monate alt
NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Neutral
The Motley Fool
3 Monate alt
Protagonist (PTGX) Q2 Revenue Falls 26%

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen